

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 21590

Title: Update on hepatitis C: Direct-acting antivirals

Reviewer's code: 00051373

Reviewer's country: Taiwan

Science editor: Fang-Fang Ji

Date sent for review: 2015-07-24 15:46

Date reviewed: 2015-07-24 21:44

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

This is an update review on the treatment of the patients with chronic C hepatitis. Of course, the extensive review can be beneficial to the reader more information on the treatment at the American and European clinics. Two comments to be concerned here: 1. It should be needed to draw a summary table for the different genotypes of hepatitis C virus and its possible response DAA. 2. The writing style of the references needs to be followed the author guideline of WJH. In my opinion, it should be accepted for publication after an adequate revision.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 21590

Title: Update on hepatitis C: Direct-acting antivirals

Reviewer's code: 00053786

Reviewer's country: Mexico

Science editor: Fang-Fang Ji

Date sent for review: 2015-07-24 15:46

Date reviewed: 2015-07-30 20:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Seifert LL et al have presented an extraordinary state-of-the-art review regarding the new era of direct-acting antivirals for HCV therapy. The authors have concisely written the effect that these new drugs have shown on SVR by genotype compared to peg-INF or RBV and the need for further studies on vaccines to finally combat HVC infection worldwide. It is a very nice integrated paper. I highly recommend publication with a few minor comments: A) The abstract does not reflect the content of the whole work, it falls short compared to the main text. The aim "The analysis of the contribution of the new DAAs to this radical change in the natural history of hepatitis C and a possible future eradication of the virus" should be placed. I suggest that each section of the paper should be summarized in the abstract. B) May the authors elaborate if possible about the side effects of DDA schemes compared to other antivirals. C) I suggest a diagram or Table to synthesize the therapeutical options given for each genotype. D) Check misspellings on page 4, the hepatitis c; on page 11, grad. Good work and congratulations!

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 21590

Title: Update on hepatitis C: Direct-acting antivirals

Reviewer's code: 00050195

Reviewer's country: Israel

Science editor: Fang-Fang Ji

Date sent for review: 2015-07-24 15:46

Date reviewed: 2015-08-03 09:35

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [Y] Accept
<input checked="" type="checkbox"/> [Y] Grade B: Very good	<input checked="" type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> [] The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	<input checked="" type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] The same title	
		<input type="checkbox"/> [] Duplicate publication	
		<input type="checkbox"/> [] Plagiarism	
		<input checked="" type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

The authors provide an extensive review of the current state of treatment for chronic HCV hepatitis. In addition they address the issue of screening and the development of a vaccine in order to both identify undiagnosed cases and also to prevent new cases. There are a few grammatical errors that need addressing. The review of the data is comprehensive- since it was submitted the FDA has approved the use of Daklinza for type 3 HCV and this could be included for the benefit of the US readers. I think a comment regarding drug interactions would be appropriate. Many of the baby boomers have co morbidities and may take medications for this. In addition there is a connection between HCV and diabetes that also results in medication. I have no further substantial comments to make.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 21590

Title: Update on hepatitis C: Direct-acting antivirals

Reviewer's code: 00012386

Reviewer's country: Japan

Science editor: Fang-Fang Ji

Date sent for review: 2015-07-24 15:46

Date reviewed: 2015-08-04 16:28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Seifert et al. reviewed the recent situation of the treatments for chronic hepatitis C. 1. In page 4, line 6 Please make corrections from 9600 kb RNA to 9.6 kb. 2. In page 4, IFN (interferon)-based, RBV (ribavirin), SVR (sustained virologic response) to interferon (IFN), ribavirin (RBV), sustained virologic response (SVR) "treatment of hepatitis c seems": hepatitis C 3. In page 5, line 12, Please make corrections from 9600 kb RNA to 9.6 kb. 4. How was core protein in structural protein?? 5. In page 7, line 11,body weight (≥ 75 kg: 1200 mg/d; < 75 kg: 1000 mg/d).?? 6. In page 11, "These excellent results from clinical trials have recently been approved by several real-life experience studies, such as the TRIO network or the HCV-TARGET consortium. Several other institutions have contributed their experience from real-life treatment of HCV-patients with DAAs in small analysis presented at the conferences of the AASLD or the EASL. The rates of SVR may be inferior to those of the presented phase III clinical trials but still very satisfactory regarding the aggravated circumstances in a real-life setting, notably concerning patient compliance." Authors should add the proper references.